Physician profile
John Lowry
NPI 1477661619
$10,034.35
in general payments reported to CMS, 2019-2025
23 companies · $2,020 in 2025
The $2,020 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $955 · 2020: $461 · 2021: $1,306 · 2022: $2,249 · 2023: $1,438 · 2024: $1,607 · 2025: $2,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,053 · Education: $10.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,053.30 |
| Education | $10.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $2,123.43 | 2021-2025 | Qelbree, Qelbree, Trokendi Xr |
| Sunovion Pharmaceuticals INC. | $1,457.36 | 2019-2022 | |
| Abbvie INC. | $1,164.53 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $885.89 | 2019-2025 | Trintellix |
| Alkermes, INC. | $855.57 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $785.38 | 2019-2025 | Ingrezza |
| Corium, LLC | $622.34 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $300.25 | 2019-2023 | Jornay Pm |
| Tris Pharma INC | $241.25 | 2019-2024 | Dyanavel Xr, Quillichew Er |
| Otsuka America Pharmaceutical, INC. | $217.02 | 2022-2025 | Rexulti |
| Lundbeck LLC | $181.53 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $167.28 | 2020-2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $154.68 | 2024-2025 | Spravato |
| Vertical Pharmaceuticals, LLC | $151.67 | 2019-2025 | Relexxii |
| Shire North American Group INC | $140.78 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $120.17 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $109.10 | 2019-2023 | Austedo Xr, Austedo |
| E.R. Squibb & Sons, L.L.C. | $108.00 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $96.09 | 2022 | |
| Allergan, INC. | $60.00 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $53.91 | 2023 | Quviviq |
| Neos Therapeutics, Lp | $25.35 | 2025 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $12.77 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.